PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pasireotide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

24 hits

Bibliografisk träff 2014-05-01

An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.

Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D, Hu K.

Am J Ther · comparative study; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1097/mjt.0b013e31824c3eb4

Bibliografisk träff 2013-01-23

Medical treatment of Cushing's disease.

Feelders RA, Hofland LJ.

J Clin Endocrinol Metab · review; journal article · DOI 10.1210/jc.2012-3126

Bibliografisk träff 2012-11-05

Involvement of bone morphogenetic protein activity in somatostatin actions on ovarian steroidogenesis.

Nakamura E, Otsuka F, Inagaki K, Tsukamoto N, Ogura-Ochi K, Miyoshi T, Toma K, Takeda M, Makino H.

J Steroid Biochem Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jsbmb.2012.10.018

Bibliografisk träff 2012-10-24

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK.

Surgery · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.surg.2012.08.021

Bibliografisk träff 2012-09-14

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.

Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH.

Endocr Relat Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1530/erc-11-0382

Bibliografisk träff 2012-09-14

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.

Endocr Relat Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1530/erc-11-0367

Bibliografisk träff 2012-09-04

Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.

Somnay Y, Chen H, Kunnimalaiyaan M.

Neuroendocrinology · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1159/000341810

Bibliografisk träff 2012-09-01

Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies.

Kokona D, Mastrodimou N, Pediaditakis I, Charalampopoulos I, Schmid HA, Thermos K.

Exp Eye Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exer.2012.08.005

Bibliografisk träff 2012-06-26

A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.

Kliewer A, Mann A, Petrich A, Pöll F, Schulz S.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0039458

Bibliografisk träff 2012-05-23

Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro.

Pecori Giraldi F, Pagliardini L, Cassarino MF, Martucci F, Sesta A, Castelli L, Montanari E, Schmid HA, Cavagnini F.

Gen Comp Endocrinol · journal article · DOI 10.1016/j.ygcen.2012.05.003

Bibliografisk träff 2012-04-19

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M.

Drug Des Devel Ther · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2147/dddt.s29125

Bibliografisk träff 2012-03-01

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

Dietrich H, Hu K, Ruffin M, Song D, Bouillaud E, Wang Y, Hasskarl J.

Eur J Endocrinol · comparative study; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1530/eje-11-0773

Bibliografisk träff 2012-01-26

Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.

Horsmans Y, Hu K, Ruffin M, Wang Y, Song D, Bouillaud E, Wang Y, Mazur D, Botha FP, Heuman DM.

J Clin Pharmacol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1177/0091270011400072

Bibliografisk träff 2011-12-14

Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.

Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, Caron P, Pyronnet S.

J Clin Endocrinol Metab · research support, non-u.s. gov't; review; journal article · DOI 10.1210/jc.2011-2088

Bibliografisk träff 2011-08-01

Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.

Imhof AK, Glück L, Gajda M, Lupp A, Bräuer R, Schaible HG, Schulz S.

Arthritis Rheum · journal article · DOI 10.1002/art.30410

Bibliografisk träff 2011-07-01

SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.

Xie Y, Chen S, Wang CH, Tang CW.

Cancer Biol Ther · journal article · DOI 10.4161/cbt.12.1.15730

Bibliografisk träff 2011-07-01

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.

Hasskarl J, Kaufmann M, Schmid HA.

Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.11.66

Bibliografisk träff 2011-06-14

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.

J Clin Pharmacol · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1177/0091270011408727

Bibliografisk träff 2011-04-28

Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.

Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera-Blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla GK, Arzt E.

Neuroendocrinology · research support, non-u.s. gov't; journal article · DOI 10.1159/000327429

Bibliografisk träff 2011-04-14

Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.

Kao YJ, Ghosh M, Schonbrunn A.

Mol Endocrinol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1210/me.2010-0398

Bibliografisk träff 2011-02-17

Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Nagel F, Doll C, Pöll F, Kliewer A, Schröder H, Schulz S.

Mol Endocrinol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1210/me.2010-0407

Bibliografisk träff 2011-01-24

Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.

Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D.

Horm Metab Res · research support, non-u.s. gov't; journal article; case reports · DOI 10.1055/s-0030-1270523

Bibliografisk träff 2010-10-21

Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells.

Tsukamoto N, Otsuka F, Miyoshi T, Inagaki K, Nakamura E, Suzuki J, Ogura T, Iwasaki Y, Makino H.

Mol Cell Endocrinol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.mce.2010.10.008

Bibliografisk träff 2010-07-16

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

Waser B, Cescato R, Tamma ML, Maecke HR, Reubi JC.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2010.07.005